Evidence map›Paper›PMID 21996738›Full record

ArticleOncogene2012

Dynamin 2 mediates PDGFRα-SHP-2-promoted glioblastoma growth and invasion.

H Feng, K W Liu, P Guo, P Zhang, T Cheng, M A McNiven, G R Johnson, B Hu, S Y Cheng

RetractedAbstract readRetracted Publication
In one paragraph

Article in Oncogene, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 49 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 2 pooled it
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. A review of Dynamin 2 involvement in cancers highlights a promising therapeutic target.Journal of experimental & clinical cancer research : CR · 2021
    Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

H FengUniversity of Pittsburgh Cancer Institute, Pittsburgh, PA 15213-1863, USA.
K W Liu
P Guo
P Zhang
T Cheng
M A McNiven
G R Johnson
B Hu
S Y Cheng
University of Pittsburgh · USAcademy of Medical Sciences · GBCenter for Drug Evaluation and Research · USMayo Clinic · US

Funding

UNIVERSITY OF PITTSBURGH CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE: BPCAUL1RR024153 · NCRR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2006 to 2011
$73.9M
University of Pittsburgh Clinical and Translational Science InstituteUL1TR000005 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2012 to 2015
$50.8M
Cytoskeletal Dynamics in Pancreatic Cancer MetastasisR01CA104125 · NCI · MAYO CLINIC ROCHESTER · PI MC NIVEN, MARK A., RAZIDLO, GINA LYNN · 2004 to 2019
$4.2M
ELMO1, Dock180 and Glioma InvasionR01CA130966 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHENG, SHI-YUAN · 2008 to 2012
$1.5M
NCATS NIH HHS UL1 TR000005NCI NIH HHS CA130966NCI NIH HHS R01 CA104125NCI NIH HHS R01 CA130966NCRR NIH HHS UL1 RR024153
6 · The paper itself

Abstract

Dynamin 2 (Dyn2), a large GTPase, is involved in receptor tyrosine kinase (RTK)-promoted cell migration. However, the molecular mechanisms by which Dyn2 regulates RTK-induced cell migration have not been established. Recently, we reported that tyrosine-protein phosphatase non-receptor type 11 (SHP-2) and phosphatidylinositol 3-kinase (PI3K) mediate platelet-derived growth factor receptor-α (PDGFRα)-promoted glioma tumor growth and invasion. Here, we show that Dyn2 is an effector downstream of the PDGFRα-PI3K/SHP-2 signaling in glioma cells. Depletion of endogenous Dyn2 by short hairpin RNAs (shRNAs) inhibited PDGFRα-stimulated phosphorylation of Akt, Erk1/2, Rac1 and Cdc42 activities, glioma cell migration and survival in vitro and tumor growth and invasion in the brains of mice. Dyn2 binds to SHP-2 and PI3K and colocalizes with PDGFRα at the invasive fronts in PDGF-A-stimulated glioma cells. Inhibition of SHP-2 by siRNA knockdown abrogated Dyn2 association with activated PDGFRα and PDGFRα activation of Rac1 and Cdc42, and glioma cell migration, thereby establishing a link between SHP-2 interaction with Dyn2 and the PDGFRα signaling. Furthermore, a dominant-negative SHP-2 C459S mutant inhibited PDGF-A-stimulated glioma cell migration, phosphorylation of Dyn2 and concomitantly blocked PDGFRα-induced Src activation. Inhibition of Src by Src inhibitors attenuated PDGF-A-stimulated phosphorylation of Akt and Dyn2 and glioma cell migration. Additionally, mutations of binding sites to PI3K, SHP-2 or Src of PDGFRα impaired PDGFRα-stimulated phosphorylation of Akt and Dyn2, and Dyn2 association with activated PDGFRα. Taken together, this study identifies Dyn2 as an effector that mediates PDGFRα-SHP-2-induced glioma tumor growth and invasion, suggesting that targeting the PDGFRα-SHP-2-Dyn2 pathway may be beneficial to patients with malignant glioblastomas.

Indexed as

AnimalsCell Line, TumorDisease ProgressionDynamin IIGene Expression Regulation, NeoplasticGene Knockdown TechniquesGenes, srcGlioblastomaHumansMiceNeoplasm InvasivenessNeoplasm TransplantationPhosphatidylinositol 3-KinasesProtein Tyrosine Phosphatase, Non-Receptor Type 11Receptor, Platelet-Derived Growth Factor alphaSignal TransductionDynamin IIPhosphatidylinositol 3-KinasesProtein Tyrosine Phosphatase, Non-Receptor Type 11PTPN11 protein, humanReceptor, Platelet-Derived Growth Factor alpha

Identifiers

PMID21996738
PMCPMC3262067
OpenAlexW2078319463

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.